ATRA works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T-cells
Last Updated: Monday, November 21, 2022
Researchers successfully used all-trans retinoic acid (ATRA) to augment B-cell maturation antigen (BCMA) to sustain BCMA expression on multiple myeloma cells and increase BCMA-CAR T-cell efficacy in pre-clinical models.
Advertisement
News & Literature Highlights